Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

4.273 -0.177 (-3.98%)
Streaming Delayed Price Updated: 2:50 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Earnings Preview: Evolus ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Evolus ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Willis Towers Watson Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Femasys Inc. (NASDAQ: FEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control. 
Via Benzinga
Evolus Inc. (NASDAQ: EOLS) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Why Shares of Evolus Are Jumping Thursday ↗
The stock climbed on record second-quarter revenue and a raise in full-year guidance. 
Via The Motley Fool
News headline image
Comcast, STMicroelectronics, Lam Research, Meta Platforms And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining around 200 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
News headline image
Expert Ratings for Evolus ↗
 
Via Benzinga
News headline image
This Analyst Likes Evolus As 'Top Play In Aesthetics' ↗
Evolus Inc (NASDAQ: EOLS) will be the exclusive U.S. 
Via Benzinga
News headline image
Expert Ratings for Evolus ↗
 
Via Benzinga
News headline image
Evolus: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Evolus Earnings Preview ↗
 
Via Benzinga
News headline image
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
From Evolus, Inc.
Via Business Wire
News headline image
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
News headline image
Twitter Faces Threats From AI and Threads ↗
AI is changing the open internet landscape, and Meta's new Threads app is looking to take a bite out of Twitter's audience. 
Via The Motley Fool
News headline image
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
News headline image
Analyst Expectations for Evolus's Future ↗
 
Via Benzinga
News headline image
Preview: Evolus's Earnings ↗
 
Via Benzinga
News headline image
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
News headline image
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
News headline image
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
News headline image
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
From Evolus, Inc.
Via Business Wire
News headline image
Evolus to Report First Quarter 2023 Results and Provide Business Update
From Evolus, Inc.
Via Business Wire
News headline image
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire
News headline image
Evolus to Participate in the Barclays Global Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Initiates Nuceiva® Launch in Germany and Austria
From Evolus, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 8, 2023 ↗
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
News headline image
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
From Evolus
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.